UNSPSC 51421903: Cortisone

This classification denotes a glucocorticoid with the molecular formula C21H28O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V27W9254FZ, chemically known as 17,21-dihydroxypregn-4-ene-3,11,20-trione but generally known as cortisone, which bears US NIH Compound Identifier 222786. European Medicines Agency schedules Cortisone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06807MIG. The term CORTISONE is an International Non-Proprietary Name.

UNSPSC 51421903 Cortisone is a Commodity code that in state and local procurement practice encompasses pharmaceutical products and medical supplies sourced for public health programs, emergency response, and community health initiatives. The recent opportunities record shows state and local governments procuring naloxone, safe drug deactivation systems, and direct-to-manufacturer prescription fulfillment capabilities under or near this code's scope. Issuing bodies include county health departments and state health and human services agencies. Seminole County, Florida represents the county-level buyer pursuing naloxone and drug deactivation systems to support community health; the Texas Health and Human Services Commission represents state-level procurement focused on pharmacy benefit program restructuring and manufacturer-direct contracting strategies. Both buyers are addressing public health priorities — opioid response and prescription cost management — through competitive procurement mechanisms.

Recent activity centers in Florida and Texas. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive sealed bid, with quarterly deliveries to the county community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription program capabilities, targeting self-insured employers and state agencies outside traditional pharmacy benefit manager arrangements. No other state or local solicitations appear in the recent-opportunities record under this code, and the code shows limited recent activity overall. The mismatch between the code's nominal scope (cortisone, a corticosteroid pharmaceutical) and the opportunities actually posted (naloxone, opioid reversal agents, and pharmacy benefit program restructuring) suggests either misclassification in the issuing bodies' coding systems or that the code has been applied broadly to pharmaceutical procurement categories beyond its discrete product name.